JNJ vs. TSLA: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at JNJ and TSLA, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | JNJ | TSLA |
|---|---|---|
| Company Name | Johnson & Johnson | Tesla, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Consumer Discretionary |
| GICS Industry | Pharmaceuticals | Automobiles |
| Market Capitalization | 425.77 billion USD | 1,127.62 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | January 2, 1962 | June 29, 2010 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of JNJ and TSLA by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | JNJ | TSLA |
|---|---|---|
| 5-Day Price Return | -1.20% | 9.21% |
| 13-Week Price Return | 15.36% | -3.66% |
| 26-Week Price Return | 8.93% | 3.49% |
| 52-Week Price Return | 7.40% | 63.97% |
| Month-to-Date Return | 7.31% | 13.41% |
| Year-to-Date Return | 22.24% | -13.43% |
| 10-Day Avg. Volume | 8.50M | 73.83M |
| 3-Month Avg. Volume | 8.25M | 102.92M |
| 3-Month Volatility | 18.04% | 56.66% |
| Beta | 0.38 | 2.04 |
Profitability
Return on Equity (TTM)
JNJ
30.39%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
In the upper quartile for the Pharmaceuticals industry, JNJ’s Return on Equity of 30.39% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
TSLA
8.22%
Automobiles Industry
- Max
- 25.70%
- Q3
- 12.88%
- Median
- 6.92%
- Q1
- 0.71%
- Min
- -15.89%
TSLA’s Return on Equity of 8.22% is on par with the norm for the Automobiles industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
JNJ
25.00%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
A Net Profit Margin of 25.00% places JNJ in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
TSLA
6.54%
Automobiles Industry
- Max
- 9.92%
- Q3
- 5.78%
- Median
- 3.23%
- Q1
- 0.11%
- Min
- -5.31%
A Net Profit Margin of 6.54% places TSLA in the upper quartile for the Automobiles industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
JNJ
30.18%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
An Operating Profit Margin of 30.18% places JNJ in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
TSLA
6.06%
Automobiles Industry
- Max
- 13.07%
- Q3
- 7.22%
- Median
- 5.29%
- Q1
- 0.43%
- Min
- -4.46%
TSLA’s Operating Profit Margin of 6.06% is around the midpoint for the Automobiles industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | JNJ | TSLA |
|---|---|---|
| Return on Equity (TTM) | 30.39% | 8.22% |
| Return on Assets (TTM) | 12.16% | 4.89% |
| Net Profit Margin (TTM) | 25.00% | 6.54% |
| Operating Profit Margin (TTM) | 30.18% | 6.06% |
| Gross Profit Margin (TTM) | 67.98% | 17.48% |
Financial Strength
Current Ratio (MRQ)
JNJ
1.01
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
JNJ’s Current Ratio of 1.01 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
TSLA
2.04
Automobiles Industry
- Max
- 2.19
- Q3
- 1.54
- Median
- 1.26
- Q1
- 1.09
- Min
- 0.48
TSLA’s Current Ratio of 2.04 is in the upper quartile for the Automobiles industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
Debt-to-Equity Ratio (MRQ)
JNJ
0.65
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
JNJ’s Debt-to-Equity Ratio of 0.65 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
TSLA
0.09
Automobiles Industry
- Max
- 2.34
- Q3
- 1.13
- Median
- 0.58
- Q1
- 0.28
- Min
- 0.06
Falling into the lower quartile for the Automobiles industry, TSLA’s Debt-to-Equity Ratio of 0.09 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio (TTM)
JNJ
34.01
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
JNJ’s Interest Coverage Ratio of 34.01 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
TSLA
71.48
Automobiles Industry
- Max
- 77.87
- Q3
- 42.86
- Median
- 13.88
- Q1
- 2.13
- Min
- -49.07
TSLA’s Interest Coverage Ratio of 71.48 is in the upper quartile for the Automobiles industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | JNJ | TSLA |
|---|---|---|
| Current Ratio (MRQ) | 1.01 | 2.04 |
| Quick Ratio (MRQ) | 0.68 | 1.35 |
| Debt-to-Equity Ratio (MRQ) | 0.65 | 0.09 |
| Interest Coverage Ratio (TTM) | 34.01 | 71.48 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
JNJ
2.81%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
JNJ’s Dividend Yield of 2.81% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
TSLA
0.00%
Automobiles Industry
- Max
- 10.71%
- Q3
- 5.39%
- Median
- 3.14%
- Q1
- 0.00%
- Min
- 0.00%
TSLA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
JNJ
53.34%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
JNJ’s Dividend Payout Ratio of 53.34% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
TSLA
0.00%
Automobiles Industry
- Max
- 114.43%
- Q3
- 59.30%
- Median
- 37.15%
- Q1
- 16.40%
- Min
- 0.00%
TSLA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | JNJ | TSLA |
|---|---|---|
| Dividend Yield (TTM) | 2.81% | 0.00% |
| Dividend Payout Ratio (TTM) | 53.34% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
JNJ
18.99
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
JNJ’s P/E Ratio of 18.99 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
TSLA
172.34
Automobiles Industry
- Max
- 27.69
- Q3
- 19.99
- Median
- 9.85
- Q1
- 6.60
- Min
- 4.25
At 172.34, TSLA’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Automobiles industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
Price-to-Sales Ratio (TTM)
JNJ
4.75
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
JNJ’s P/S Ratio of 4.75 is in the upper echelon for the Pharmaceuticals industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
TSLA
11.27
Automobiles Industry
- Max
- 1.52
- Q3
- 0.84
- Median
- 0.41
- Q1
- 0.23
- Min
- 0.08
With a P/S Ratio of 11.27, TSLA trades at a valuation that eclipses even the highest in the Automobiles industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio (MRQ)
JNJ
4.68
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
JNJ’s P/B Ratio of 4.68 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
TSLA
13.23
Automobiles Industry
- Max
- 4.25
- Q3
- 2.00
- Median
- 0.87
- Q1
- 0.46
- Min
- 0.19
At 13.23, TSLA’s P/B Ratio is at an extreme premium to the Automobiles industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | JNJ | TSLA |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 18.99 | 172.34 |
| Price-to-Sales Ratio (TTM) | 4.75 | 11.27 |
| Price-to-Book Ratio (MRQ) | 4.68 | 13.23 |
| Price-to-Free Cash Flow Ratio (TTM) | 23.20 | 187.03 |